filmov
tv
EMBL Forum Science and Society Seminar: Fabrizio Benedetti - The placebo effect
Показать описание
The placebo effect: How words and rituals change the patient’s brain
Fabrizio Benedetti, University of Turin Medical School and at the National Institute of Neuroscience in Italy (3 March 2011)
Although placebos have long been considered a nuisance in clinical research, today they represent an active and productive field of research and, due to the involvement of many mechanisms, the study of the placebo effect can actually be viewed as a melting pot of concepts and ideas for neuroscience. Indeed, there exist not a single placebo effect, but many, with different mechanisms and in different systems, medical conditions and therapeutic interventions.
For example, brain mechanisms of expectation, anxiety and reward are all involved, as well as a variety of learning phenomena, such as Pavlovian conditioning, cognitive and social learning. There is also some experimental evidence of different genetic variants in placebo responsiveness. The most productive models to better understand the neurobiology of the placebo effect are pain and Parkinson’s disease. In these medical conditions, the neural networks that are involved have been identified: that is, an opioidergic-cholecystokinergic-dopaminergic modulatory network in pain and part of the basal ganglia circuitry in Parkinson’s disease.
Important clinical implications emerge from these recent advances in placebo research. First, as the placebo effect is basically a psychosocial context effect, these data indicate that different social stimuli, such as words and rituals of the therapeutic act, may change the chemistry and circuitry of the patient’s brain. Second, the mechanisms that are activated by placebos are the same as those activated by drugs, which suggests a cognitive/affective interference with drug action. Third, if prefrontal functioning is impaired, placebo responses are reduced or totally lacking, as occurs in dementia of the Alzheimer’s type.
Established in 1998, the principal aim of the Science and Society initiative at EMBL is to promote a better and broader understanding of the growing social and cultural relevance of the life sciences. We invite speakers – experts within various disciplines of science and the humanities – on a regular basis to the EMBL to give public lectures on topics of interest.
Fabrizio Benedetti, University of Turin Medical School and at the National Institute of Neuroscience in Italy (3 March 2011)
Although placebos have long been considered a nuisance in clinical research, today they represent an active and productive field of research and, due to the involvement of many mechanisms, the study of the placebo effect can actually be viewed as a melting pot of concepts and ideas for neuroscience. Indeed, there exist not a single placebo effect, but many, with different mechanisms and in different systems, medical conditions and therapeutic interventions.
For example, brain mechanisms of expectation, anxiety and reward are all involved, as well as a variety of learning phenomena, such as Pavlovian conditioning, cognitive and social learning. There is also some experimental evidence of different genetic variants in placebo responsiveness. The most productive models to better understand the neurobiology of the placebo effect are pain and Parkinson’s disease. In these medical conditions, the neural networks that are involved have been identified: that is, an opioidergic-cholecystokinergic-dopaminergic modulatory network in pain and part of the basal ganglia circuitry in Parkinson’s disease.
Important clinical implications emerge from these recent advances in placebo research. First, as the placebo effect is basically a psychosocial context effect, these data indicate that different social stimuli, such as words and rituals of the therapeutic act, may change the chemistry and circuitry of the patient’s brain. Second, the mechanisms that are activated by placebos are the same as those activated by drugs, which suggests a cognitive/affective interference with drug action. Third, if prefrontal functioning is impaired, placebo responses are reduced or totally lacking, as occurs in dementia of the Alzheimer’s type.
Established in 1998, the principal aim of the Science and Society initiative at EMBL is to promote a better and broader understanding of the growing social and cultural relevance of the life sciences. We invite speakers – experts within various disciplines of science and the humanities – on a regular basis to the EMBL to give public lectures on topics of interest.
Комментарии